Defying convention.

As leaders in the life sciences, our Directors share our vision for the potential of Synthetic Biotic medicines and challenge us daily to achieve more to advance our mission. Having served at the helm of biotechnology companies and investment firms, our Directors serve as strategic partners and advisors guiding us to achieve progress for patients and the field.

Peter Barrett, PhD

Chairman, Partner, Atlas Venture

Aoife Brennan, MB, BCh, BAO, MRCPI

President and Chief Executive Officer

Mike Burgess, MB, ChB, PhD

President, Research & Development, Turnstone Biologics

Nick Leschly

CEO, 2seventy bio

Ed Mathers

Partner, New Enterprise Associates

Richard P. Shea

CFO, Syndax Pharmaceuticals

Patricia N. Hurter, PHD

CEO, Lyndra Therapeutics

Michael Heffernan

Chairman, Collegium Pharmaceutical

Lisa Kelly-Croswell

Senior Vice President and CHRO for Boston Medical Center Health System